title: Androgenetic alopecia in men: the scale of the problem and prospects for treatment.
abstract: While the precise incidence of androgenetic alopecia is unknown, it is universally acknowledged to be the most common hair problem in men. Balding is generally associated with ageing; consequently, the desire to prolong a youthful appearance inevitably leads to demands for effective treatments. Further, changing attitudes in modern society have resulted in people becoming concerned about their appearance and less tolerant about conditions that might be alleviated by medical intervention. The importance of hair loss upon quality of life has been underestimated by the medical profession. Clinicians failing to accept hair loss as an important medical problem ignore the real distress suffered by a significant proportion of those affected. New options for treatment that selectively target the metabolic pathways involved in the balding process are showing promise. The first generation of such drugs, Propecia, is now available in some countries and other molecules are currently under development.
authors.affiliation: School of Pharmacy and Biomedical Sciences, University of Portsmouth, Hants.
authors.forename: D H
authors.initials: DH
authors.lastname: Rushton
mesh_terms: D000328:Adult; D000505:Alopecia / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology / Q000523:psychology; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001828:Body Image; D004739:England / Q000453:epidemiology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D008914:Minoxidil / Q000627:therapeutic use*; D011788:Quality of Life; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D004791:Enzyme Inhibitors; D014665:Vasodilator Agents; D018120:Finasteride; D008914:Minoxidil